• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Wyeth Overhauling Phase II Program

Wyeth Overhauling Phase II Program

July 18, 2006
CenterWatch Staff

Wyeth plans to make bold changes to its phase II program, cutting the number of sites participating and using more sites in China, India, Latin America and Central and Eastern Europe. Wyeth also plans to use more sites in emerging regions for its entire clinical program.

Wyeth has a robust pipeline of compounds entering phase II. While phase II clinical trials study a relatively small population of no more than a few hundred subjects, Wyeth uses 50 to 100 sites, 30% of which enroll zero to two patients for phase II trials. This practice is common among most large international pharmaceutical companies. Wyeth plans to reduce the number of sites in a typical phase II program to about 10-20 worldwide...

The key reasons for the overhaul are faster time to market, potentially higher data quality and lower costs. The logistics involved in having 50 to 100 sites participate in a phase II program are formidable. In addition, grant costs in the U.S. and Western Europe are high. Wyeth will increase its use of sites in China, India, Latin America and Central and Eastern Europe, where it will have access to large populations of treatment-naïve patients. In these emerging regions healthcare is centralized at very large hospitals that see thousands of patients per day, which can speed patient enrollment in a clinical trial considerably.

Wyeth will still have sites in the U.S. and Western Europe. The ratio of core countries for not only the phase II program but for Wyeth’s entire clinical program will be about 55% core countries and 45% rest of world. Asia Pacific will make up about 25% and most of that will be in India and China. The company believes that by doing the majority of its phase II trials with only 10 to 20 sites it will cut patient enrollment times in half. Patient enrollment is a major cause of delay in drug development, so cutting that time will mean reducing time to market. In addition, by focusing on fewer sites, Wyeth potentially will be able to get higher quality data, reducing data cleaning times and, in turn, also speeding time to market.

Wyeth has already identified 10 to 15 sites, contracted with five and will sign with five more by year’s end. Wyeth plans to have 15 sites up and running by April 2007. If successful, other large international pharmaceutical companies may follow suit. Wyeth’s daring new phase II initiative could revolutionize drug development as we know it.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing